Treatment of131I-labeled anti-CD147 monoclonal antibody in VX2 carcinoma-induced liver tumors

Oncology Reports

Volumn 30, Issue 1, 2013, Pages 246-252

  Niu, Huanzhang ^a,b   Wang, Ruihua ^b   Cheng, Jingliang ^b   Gao, Shegan ^a   Liu, Baoping ^b  

^a HENAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b ZHENGZHOU UNIVERSITY   (China)

Author keywords

131I; CD147; Liver cancer; Transcatheter arterial infusion

Indexed keywords

ANTINEOPLASTIC AGENT; CD31 ANTIGEN; GELATINASE A; IOHEXOL; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD147 I 131; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DIGITAL SUBTRACTION ANGIOGRAPHY; DRUG EFFICACY; DRUG RESPONSE; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; LIFESPAN; LIVER ANGIOGRAPHY; LIVER CELL CARCINOMA; METASTASIS INHIBITION; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT DURATION; TUMOR NECROSIS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD147; ANTIGENS, CD31; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; IODINE RADIOISOTOPES; LIVER; LIVER NEOPLASMS; MATRIX METALLOPROTEINASE 2; NECROSIS; NEOPLASM METASTASIS; RABBITS;

EID: 84878189095     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2418     Document Type: Article

References (36)

1. Parkin DM, Bray F, Ferlay J and Pisani P: Estimating the world cancer burden: Globocan 2000. Int J Cancer 94: 153-156, 2001. (Pubitemid 32911406)
2. Llovet JM, Burroughs A and Bruix J: Hepatocellular carcinoma. Lancet 362: 1907-1917, 2003. (Pubitemid 37518510)
3. Jelic S: Hepatocellular carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 20 (Suppl 4): 41-45, 2009.
4. Lai EC, Fan ST, Lo CM, Chu KM, Liu CL and Wong J: Hepatic resection for hepatocellular carcinoma. An audit of 343 patients. Ann Surg 221: 291-298, 1995.
5. No authors listed: A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire. N Engl J Med 332: 1256-1261, 1995.
6. Schwartz JD and Beutler AS: Therapy for unresectable hepatocellular carcinoma: review of the randomized clinical trials-II: systemic and local non-embolization-based therapies in unresectable and advanced hepatocellular carcinoma. Anticancer Drugs 15: 439-452, 2004. (Pubitemid 38736941)
7. Biswas C: Tumor cell stimulation of collagenase production by fibroblasts. Biochem Biophys Res Commun 109: 1026-1034, 1982.
8. Biswas C, Zhang Y, DeCastro R, et al: The human tumor cell-derived collagenase stimulatory factor (renamed EMMPRIN) is a member of the immunoglobulin superfamily. Cancer Res 55: 434-439, 1995.
9. Philp NJ, Ochrietor JD, Rudoy C, Muramatsu T and Linser PJ: Loss of MCT1, MCT3, and MCT4 expression in the retinal pigment epithelium and neural retina of the 5A11/basigin-null mouse. Invest Ophthalmol Vis Sci 44: 1305-1311, 2003. (Pubitemid 36297854)
10. Guo H, Zucker S, Gordon MK, Toole BP and Biswas C: Stimulation of matrix metalloproteinase production by recombinant extracellular matrix metalloproteinase inducer from transfected Chinese hamster ovary cells. J Biol Chem 272: 24-27, 1997. (Pubitemid 27021117)
11. Zhu S, Li Y, Mi L, et al: Clinical impact of HAb18G/CD147 expression in esophageal squamous cell carcinoma. Dig Dis Sci 56: 3569-3576, 2011.
12. Zhong WD, Liang YX, Lin SX, et al: Expression of CD147 is associated with prostate cancer progression. Int J Cancer 130: 300-308, 2012.
13. Liu F, Cui L, Zhang Y, et al: Expression of HAb18G is associated with tumor progression and prognosis of breast carcinoma. Breast Cancer Res Treat 124: 677-688, 2010.
14. He HC, Han ZD, Dai QS, et al: Expression and significance of CD147 protein in prostate cancer. Zhonghua Yi Xue Za Zhi 89: 1844-1846, 2009 (In Chinese).
15. Xu J, Xu HY, Zhang Q, et al: HAb18G/CD147 functions in invasion and metastasis of hepatocellular carcinoma. Mol Cancer Res 5: 605-614, 2007. (Pubitemid 46985049)
16. Redondo P, Lloret P, Idoate M and Inoges S: Expression and serum levels of MMP-2 and MMP-9 during human melanoma progression. Clin Exp Dermatol 30: 541-545, 2005. (Pubitemid 41076024)
17. Kawamura K, Kamiya N, Suyama T, et al: In situ gelatinolytic activity correlates with tumor progression and prognosis in patients with bladder cancer. J Urol 172: 1480-1484, 2004. (Pubitemid 39249753)
18. Sun J and Hemler ME: Regulation of MMP-1 and MMP-2 production through CD147/extracellular matrix metalloproteinase inducer interactions. Cancer Res 61: 2276-2281, 2001. (Pubitemid 32692059)
19. Xu J, Shen ZY, Chen XG, et al: A randomized controlled trial of Licartin for preventing hepatoma recurrence after liver transplantation. Hepatology 45: 269-276, 2007. (Pubitemid 46374583)
20. Kanekura T, Chen X and Kanzaki T: Basigin (CD147) is expressed on melanoma cells and induces tumor cell invasion by stimulating production of matrix metalloproteinases by fibroblasts. Int J Cancer 99: 520-528, 2002. (Pubitemid 34461604)
21. Llovet JM, Real MI, Montana X, et al: Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359: 1734-1739, 2002. (Pubitemid 34607087)
22. Hansler J, Neureiter D, Wasserburger M, et al: Percutaneous US-guided radiofrequency ablation with perfused needle applicators: improved survival with the VX2 tumor model in rabbits. Radiology 230: 169-174, 2004. (Pubitemid 37549798)
23. Yoon CJ, Chung JW, Park JH, et al: Transcatheter arterial chemoembolization with paclitaxel-lipiodol solution in rabbit VX2 liver tumor. Radiology 229: 126-131, 2003. (Pubitemid 37152114)
24. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216, 2000.
25. Zhang Z, Bian H, Feng Q, et al: Biodistribution and localization of iodine-131-labeled metuximab in patients with hepatocellular carcinoma. Cancer Biol Ther 5: 318-322, 2006.
26. Yamaguchi R, Yano H, Iemura A, Ogasawara S, Haramaki M and Kojiro M: Expression of vascular endothelial growth factor in human hepatocellular carcinoma. Hepatology 28: 68-77, 1998. (Pubitemid 28299987)
27. Weidner N, Semple JP, Welch WR and Folkman J: Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J Med 324: 1-8, 1991.
28. Hamaguchi S, Tohnai I, Ito A, et al: Selective hyperthermia using magnetoliposomes to target cervical lymph node metastasis in a rabbit tongue tumor model. Cancer Sci 94: 834-839, 2003. (Pubitemid 37258784)
29. Marelli L, Stigliano R, Triantos C, et al: Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 30: 6-25, 2007. (Pubitemid 44900485)
30. Biolato M, Marrone G, Racco S, et al: Transarterial chemoembolization (TACE) for unresectable HCC: a new life begins? Eur Rev Med Pharmacol Sci 14: 356-362, 2010.
31. Yang Y, Lu N, Zhou J, Chen ZN and Zhu P: Cyclophilin A up-regulates MMP-9 expression and adhesion of monocytes/macrophages via CD147 signalling pathway in rheumatoid arthritis. Rheumatology 47: 1299-1310, 2008.
32. Dai JY, Dou KF, Wang CH, et al: The interaction of HAb18G/CD147 with integrin alpha6beta1 and its implications for the invasion potential of human hepatoma cells. BMC Cancer 9: 337, 2009.
33. Zhou J, Zhu P, Jiang JL, et al: Involvement of CD147 in overexpression of MMP-2 and MMP-9 and enhancement of invasive potential of PMA-differentiated THP-1. BMC Cell Biol 6: 25, 2005.
34. Stewart CJ and Crook ML: CD147 (EMMPRIN) and matrix metalloproteinase-2 expression in uterine endometrioid adenocarcinoma. Pathol Res Pract 207: 30-36, 2011.
35. Afonso J, Longatto-Filho A, Baltazar F, et al: CD147 overexpression allows an accurate discrimination of bladder cancer patients' prognosis. Eur J Surg Oncol 37: 811-817, 2011.
36. Voigt H, Vetter-Kauczok CS, Schrama D, Hofmann UB, Becker JC and Houben R: CD147 impacts angiogenesis and metastasis formation. Cancer Invest 27: 329-333, 2009.